BR112020024328A2 - inibidor de ccr5 para uso no tratamento de câncer - Google Patents

inibidor de ccr5 para uso no tratamento de câncer Download PDF

Info

Publication number
BR112020024328A2
BR112020024328A2 BR112020024328-0A BR112020024328A BR112020024328A2 BR 112020024328 A2 BR112020024328 A2 BR 112020024328A2 BR 112020024328 A BR112020024328 A BR 112020024328A BR 112020024328 A2 BR112020024328 A2 BR 112020024328A2
Authority
BR
Brazil
Prior art keywords
seq
cancer
ccr5
fact
ccr5 inhibitor
Prior art date
Application number
BR112020024328-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Oliver Hartley
Robin Ewart Offord
Original Assignee
Orion Biotechnology Switzerland Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Biotechnology Switzerland Sàrl filed Critical Orion Biotechnology Switzerland Sàrl
Publication of BR112020024328A2 publication Critical patent/BR112020024328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112020024328-0A 2018-05-28 2019-05-24 inibidor de ccr5 para uso no tratamento de câncer BR112020024328A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US62/677,114 2018-05-28
US201962792600P 2019-01-15 2019-01-15
US62/792,600 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
BR112020024328A2 true BR112020024328A2 (pt) 2021-02-23

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020024328-0A BR112020024328A2 (pt) 2018-05-28 2019-05-24 inibidor de ccr5 para uso no tratamento de câncer

Country Status (11)

Country Link
US (1) US20210205411A1 (enExample)
EP (1) EP3813870B1 (enExample)
JP (2) JP7319020B2 (enExample)
KR (1) KR20210016398A (enExample)
CN (1) CN112469429B (enExample)
AU (1) AU2019276939A1 (enExample)
BR (1) BR112020024328A2 (enExample)
CA (1) CA3101556A1 (enExample)
MX (1) MX2020012782A (enExample)
WO (1) WO2019229616A1 (enExample)
ZA (1) ZA202007955B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729023A (zh) * 2019-04-01 2022-07-08 西托戴恩股份有限公司 阻断癌症转移或增强由dna损伤化学疗法诱导的细胞死亡的抗ccr5药剂和治疗方法
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
EP3693041A1 (en) * 2011-06-13 2020-08-12 TLA Targeted Immunotherapies AB Treating cancer
HK1209673A1 (en) * 2012-05-14 2016-04-08 Prostagene Llc Using modulators of ccr5 for treating cancer
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US20180289689A1 (en) * 2014-10-27 2018-10-11 Ruprecht-Karls-Universität Heidelberg Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Also Published As

Publication number Publication date
JP7319020B2 (ja) 2023-08-01
AU2019276939A1 (en) 2021-01-21
EP3813870B1 (en) 2023-11-15
US20210205411A1 (en) 2021-07-08
MX2020012782A (es) 2021-04-28
CA3101556A1 (en) 2019-12-05
JP2021525770A (ja) 2021-09-27
EP3813870C0 (en) 2023-11-15
ZA202007955B (en) 2022-06-29
CN112469429B (zh) 2025-02-14
KR20210016398A (ko) 2021-02-15
EP3813870A1 (en) 2021-05-05
JP2023134704A (ja) 2023-09-27
CN112469429A (zh) 2021-03-09
WO2019229616A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
EP3813870B1 (en) Ccr5 inhibitor for use in treating cancer
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
ES2940302T3 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
WO2012050374A2 (en) Immunotherapy for solid tumors
CN102908346A (zh) 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途
US7893045B2 (en) Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US7816323B2 (en) Methods of using corticotropin-releasing factor for the use of the treatment of cancer
US20120183536A1 (en) Methods of using corticotropin-releasing factor for the treatment of cancer
WO2004065572A2 (en) Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
HK40048943A (en) Ccr5 inhibitor for use in treating cancer
US20100113341A1 (en) Methods of using corticotropin-releasing factor for the treatment of cancer
KR20090061358A (ko) 아카세틴을 유효성분으로 하는 유방암 예방 및 치료용조성물
WO2008036954A1 (en) Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
US11529363B2 (en) Methods of treating cancer in pediatric patients
EP4376960A1 (en) Concurrent targeting of oncogenic pathways to enhance chemotherapy and immunotherapy
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물
AU2016204119B2 (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CA2670301A1 (en) Inhibition of metastasis using activated protein c

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2881 DE 24-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.